journal
Journals European Journal of Medicinal ...

European Journal of Medicinal Chemistry

https://read.qxmd.com/read/37257211/discovery-of-new-tetrahydroisoquinolines-as-potent-and-selective-lsd1-inhibitors-for-the-treatment-of-mll-rearranged-leukemia
#1
JOURNAL ARTICLE
Chao Yang, Yuan Fang, Yaxuan Hu, Tiantian Tian, Guochao Liao
Histone lysine-specific demethylase 1 (LSD1) is a promising target for cancer therapy. Here, we performed the design, synthesis, and extensive structure-activity relationship (SAR) studies based on our previously discovered natural LSD1 inhibitor, higenamine. We found that the tetracyclic tetrahydroisoquinoline FY-21 is a potent and selective inhibitor of LSD1 (IC50  = 340 nM). FY-21 inhibited leukemia cell proliferation and colony formation and increased the level of p53 expression. Meanwhile, FY-21 reduced the mRNA levels of the transcription factors HOXA9 and MEIS1...
May 25, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37262997/discovery-of-a-high-potent-pim-kinase-inhibitor-for-acute-myeloid-leukemia-based-on-n-pyridinyl-amide-scaffold-by-optimizing-the-fragments-toward-to-lys67-and-asp128-glu171
#2
JOURNAL ARTICLE
Ruiqing Xiang, Mingzhu Lu, Tianze Wu, Chengbin Yang, Yu Jia, Xiaofeng Liu, Mingli Deng, Yu Ge, Jun Xu, Tong Cai, Yun Ling, Yaming Zhou
Despite the recent development of PIM inhibitors based on N-(pyridin-3-yl)acetamide scaffold for acute myeloid leukemia (AML), the structural-activity relationship (SAR) associated with the effects of positional isomerization of N toward to Lys67 and freedom of solvent fragment toward to Asp128/Glu171 still remains an open question. In this work, a structurally novel compound based on N-pyridinyl amide was designed by fragment hybridization and then our SAR exploration revealed that the positional isomerization would lead to a decrease in activity, while increase of the freedom of solvent fragment by breaking the intramolecular hydrogen bond unprecedentedly leads to an increase in activity...
May 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37257212/discovery-of-quinazolin-4-one-based-non-covalent-inhibitors-targeting-the-severe-acute-respiratory-syndrome-coronavirus-2-main-protease-sars-cov-2-m-pro
#3
JOURNAL ARTICLE
Kuojun Zhang, Tianyu Wang, Maotian Li, Mu Liu, He Tang, Lin Wang, Ke Ye, Jiamei Yang, Sheng Jiang, Yibei Xiao, Youhua Xie, Meiling Lu, Xiangyu Zhang
The COVID-19 pandemic caused by SARS-CoV-2 continues to pose a great threat to public health while various vaccines are available worldwide. Main protease (Mpro ) has been validated as an effective anti-COVID-19 drug target. Using medicinal chemistry and rational drug design strategies, we identified a quinazolin-4-one series of nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitors based on baicalein, 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one. In particular, compound C7 exhibits superior inhibitory activity against SARS-CoV-2 Mpro relative to baicalein (IC50  = 0...
May 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37253308/development-of-a-next-generation-endogenous-oct4-inducer-and-its-anti-aging-effect-in-vivo
#4
JOURNAL ARTICLE
Han Kang, Sebastian Hasselbeck, Katerina Taškova, Nessa Wang, Luuk N van Oosten, Ralf Mrowka, Jochen Utikal, Miguel A Andrade-Navarro, Jichang Wang, Stefan Wölfl, Xinlai Cheng
The identification of small molecules capable of replacing transcription factors has been a longstanding challenge in the generation of human chemically induced pluripotent stem cells (iPSCs). Recent studies have shown that ectopic expression of OCT4, one of the master pluripotency regulators, compromised the developmental potential of resulting iPSCs, This highlights the importance of finding endogenous OCT4 inducers for the generation of clinical-grade human iPSCs. Through a cell-based high throughput screen, we have discovered several new OCT4-inducing compounds (O4Is)...
May 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37247505/the-emerging-role-of-mixed-lineage-kinase-3-mlk3-and-its-potential-as-a-target-for-neurodegenerative-diseases-therapies
#5
REVIEW
Ricardo Moreno, Javier Recio, Santiago Barber, Carmen Gil, Ana Martinez
Selective and brain-permeable protein kinase inhibitors are in preclinical development for treating neurodegenerative diseases. Among them, MLK3 inhibitors, with a potent neuroprotective biological action have emerged as valuable agents for the treatment of pathologies such as Alzheimer's, Parkinson's disease and amyotrophic lateral sclerosis. In fact, one MLK3 inhibitor, CEP-1347, reached clinical trials for Parkinson's disease. Additionally, another compound called prostetin/12k, a potent and rather selective MLK3 inhibitor has started clinical development for ALS based on its motor neuron protection in both in vitro and in vivo models...
May 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37253309/design-synthesis-and-biological-evaluation-of-peptidomimetic-benzothiazolyl-ketones-as-3cl-pro-inhibitors-against-sars-cov-2
#6
JOURNAL ARTICLE
Hanxi Yang, Mengyuan You, Xiaoyang Shu, Jingyao Zhen, Mengwei Zhu, Tiantian Fu, Yan Zhang, Xiangrui Jiang, Leike Zhang, Yechun Xu, Yumin Zhang, Haixia Su, Qiumeng Zhang, Jingshan Shen
A series of peptidomimetic compounds containing benzothiazolyl ketone and [2.2.1] azabicyclic ring was designed, synthesized and evaluated in the hope of obtaining potent oral 3CLpro inhibitors with improved pharmacokinetic properties. Among the target compounds, 11b had the best enzymatic potency (IC50  = 0.110 μM) and 11e had the best microsomal stability (t1/2  > 120 min) and good enzyme activity (IC50  = 0.868 μM). Therefore, compounds 11b and 11e were chosen for further evaluation of pharmacokinetics in ICR mice...
May 23, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37247506/structure-affinity-relationships-of-stereoisomers-of-norbenzomorphan-derived-%C3%AF-2-r-tmem97-modulators
#7
JOURNAL ARTICLE
Yan Lu, Qi Gu, Stephen F Martin
The sigma 2 receptor (σ2 R), which is identical to transmembrane protein 97 (TMEM97), is attracting increasing interest as a possible therapeutic target for various indications in neuroscience. In continuation of a program to identify novel compounds that bind with high affinity and selectivity to σ2 R/TMEM97, we performed structure-affinity-relationship (SAfiR) studies of several sets of σ2 R/TMEM97 ligands having a B-norbenzomorphan ring core. Binding data for σ2 R/TMEM97 and σ1 R of several enantiomeric pairs of piperazine-substituted norbenzomorphans show the (1S,5R)-enantiomers have affinities (Ki  = 9-75 nM) for σ2 R/TMEM97 that are 2-3-fold higher than their enantiomorphic (1R,5S)-analogs; however, there is no clear trend for selectivity for σ2 R/TMEM97 vs σ1 R...
May 23, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37244162/the-research-progress-of-sars-cov-2-main-protease-inhibitors-from-2020-to-2022
#8
REVIEW
Xiaojing Pang, Wei Xu, Yang Liu, Hua Li, Lixia Chen
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro ) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design...
May 22, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37262998/discovery-of-new-imidazotetrazinones-with-potential-to-overcome-tumor-resistance
#9
JOURNAL ARTICLE
Helen S Summers, William Lewis, Huw E L Williams, Tracey D Bradshaw, Christopher J Moody, Malcolm F G Stevens
We describe the design, organic synthesis, and characterization, including X-ray crystallography, of a series of novel analogues of the clinically used antitumor agent temozolomide, together with their in vitro biological evaluation. The work has resulted in the discovery of a new series of anticancer imidazotetrazines that offer the potential to overcome the resistance mounted by tumors against temozolomide. The rationally designed compounds that incorporate a propargyl alkylating moiety and a thiazole ring as isosteric replacement for a carboxamide, are readily synthesized (gram-scale), exhibit defined solid-state structures, and enhanced growth-inhibitory activity against human tumor cell lines, including MGMT-expressing and MMR-deficient lines, molecular features that confer tumor resistance...
May 21, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37235999/development-of-a-mmae-based-antibody-drug-conjugate-targeting-b7-h3-for-glioblastoma
#10
JOURNAL ARTICLE
Yurong Mao, Ding Wei, Fengqing Fu, Huihui Wang, Ziyu Sun, Ziyi Huang, Yan Wang, Guangbo Zhang, Xueguang Zhang, Biao Jiang, Hongli Chen
B7-H3 (immunoregulatory protein B7-homologue 3) is overexpressed in many cancer cells with limited expression in normal tissues, considered to be a promising target for tumor therapeutics. Clinical trials of antibody-drug conjugates (ADCs) against different targets for glioblastoma have been investigated and showed potent efficacies. In this study, we developed a homogeneous ADC 401-4 with a drug-to-antibody ratio (DAR) of 4, which was prepared by conjugation of Monomethyl auristatin E (MMAE) to a humanized anti-B7-H3 mAb 401, through a divinylsulfonamide-mediated disulfide re-bridging approach...
May 20, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37267753/1-3-thiazole-derivatives-as-privileged-structures-for-anti-trypanosoma-cruzi-activity-rational-design-synthesis-in-silico-and-in-vitro-studies
#11
JOURNAL ARTICLE
Mabilly Cox Holanda de Barros Dias, Mayara Souza Barbalho, Gevanio Bezerra de Oliveira Filho, Marcos Veríssimo de Oliveira Cardoso, Ana Cristina Lima Leite, Aline Caroline da Silva Santos, Ana Catarina Cristovão Silva, Maria Carolina Accioly Brelaz de Castro, Danielle Maria Nascimento Moura, Luiz Felipe Gomes Rebello Ferreira, Marcelo Zaldini Hernandes, Rafael de Freitas E Silva, Valéria Rêgo Alves Pereira
Chagas disease is a deadly and centenary neglected disease that is recently surging as a potential global threat. Approximately 30% of infected individuals develop chronic Chagas cardiomyopathy and current treatment with the reference benznidazole (BZN) is ineffective for this stage. We presently report the structural planning, synthesis, characterization, molecular docking prediction, cytotoxicity, in vitro bioactivity and mechanistic studies on the anti-T. cruzi activity of a series of 16 novel 1,3-thiazoles (2-17) derived from thiosemicarbazones (1a, 1b) in a two-step and reproducible Hantzsch-based synthesis approach...
May 19, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37244161/hiv-1-protease-inhibitors-with-a-p1-phosphonate-modification-maintain-potency-against-drug-resistant-variants-by-increased-interactions-with-flap-residues
#12
JOURNAL ARTICLE
Gordon J Lockbaum, Linah N Rusere, Mina Henes, Klajdi Kosovrasti, Desaboini Nageswara Rao, Ean Spielvogel, Sook-Kyung Lee, Ellen A Nalivaika, Ronald Swanstrom, Nese Kurt Yilmaz, Celia A Schiffer, Akbar Ali
Protease inhibitors are the most potent antivirals against HIV-1, but they still lose efficacy against resistant variants. Improving the resistance profile is key to developing more robust inhibitors, which may be promising candidates for simplified next-generation antiretroviral therapies. In this study, we explored analogs of darunavir with a P1 phosphonate modification in combination with increasing size of the P1' hydrophobic group and various P2' moieties to improve potency against resistant variants. The phosphonate moiety substantially improved potency against highly mutated and resistant HIV-1 protease variants, but only when combined with more hydrophobic moieties at the P1' and P2' positions...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37236000/discovery-structural-optimization-and-anti-tumor-bioactivity-evaluations-of-betulinic-acid-derivatives-as-a-new-type-of-ror%C3%AE-antagonists
#13
JOURNAL ARTICLE
Lianghe Mei, Lansong Xu, Sanan Wu, Yafang Wang, Chao Xu, Lin Wang, Xingyu Zhang, Chengcheng Yu, Hualiang Jiang, Xianglei Zhang, Fang Bai, Chengying Xie
Betulinic acid (BA) is a natural pentacyclic triterpenoid that has a wide range of biological and pharmacological effects. Here, computational methods such as pharmacophore screening and reverse docking were used to predict the potential target for BA. Retinoic acid receptor-related orphan receptor gamma (RORγ) was confirmed as its target by several molecular assays as well as crystal complex structure determination. RORγ has been the focus of metabolic regulation, but its potential role in cancer treatment has only recently come to the fore...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37229832/design-synthesis-and-biological-evaluation-of-4-4-aminophenoxy-picolinamide-derivatives-as-potential-antitumor-agents
#14
JOURNAL ARTICLE
Jintian Dai, Jianqing Zhang, Dongxue Fu, Meng Liu, Han Zhang, Sheng Tang, Linxiao Wang, Shan Xu, Wufu Zhu, Qidong Tang, Pengwu Zheng, Ting Chen
Cancer is a leading cause of death in humans. Molecular targeted therapy for cancer has become a research hotspot as it is associated with low toxicity and high efficiency. In this study, a total of 36 derivatives of 4-(4-aminophenoxy)pyridinamide were designed and synthesized, based on the analysis of the binding patterns of cabozantinib and BMS-777607 to MET protein. Most target compounds exhibited moderate to excellent antiproliferative activity against three different cell lines (A549, HeLa and MCF-7). A total of 7 compounds had stronger inhibitory activities than cabozantinib, and the IC50 value of the most promising compound 46 was 0...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37229831/bench-to-bedside-innovation-of-small-molecule-anti-sars-cov-2-drugs-in-china
#15
JOURNAL ARTICLE
Liyan Yang, Zhonglei Wang
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2. Small molecule inhibitors (remdesivir, Paxlovid, and molnupiravir) are essential complements to vaccines and play important roles in clinical treatment of SARS-CoV-2. Many advances have been made in development of anti-SARS-CoV-2 inhibitors in China, but progress in discovery and characterization of pharmacological activity, antiviral mechanisms, and clinical efficacy are limited...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37224761/sulfur-fluoride-exchange-sufex-enabled-lead-discovery-of-ache-inhibitors-by-fragment-linking-strategies
#16
JOURNAL ARTICLE
Ziwen Zhang, Shi-Long Zhang, Chengyao Wu, Huan-Huan Li, Liang Zha, Jingbo Shi, Xinhua Liu, Hua-Li Qin, Wenjian Tang
SuFEx click chemistry has been a method for the rapid synthesis of functional molecules with desirable properties. Here, we demonstrated a workflow that allows for in situ synthesis of sulfonamide inhibitors based on SuFEx reaction for high-throughput testing of their cholinesterase activity. According to fragment-based drug discovery (FBDD), sulfonyl fluorides [R-SO2 F] with moderate activity were identified as fragment hits, rapidly diversified into 102 analogs in SuFEx reactions, and the sulfonamides were directly screened to yield drug-like inhibitors with 70-fold higher potency (IC50  = 94 nM)...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37216812/development-of-isoselenazolium-chlorides-as-selective-pyruvate-kinase-isoform-m2-inhibitors
#17
JOURNAL ARTICLE
Pavels Dimitrijevs, Marina Makrecka-Kuka, Agnieszka Bogucka, Marko Hyvönen, Teodors Pantelejevs, Pavel Arsenyan
Alterations in cancer metabolic pathways open up an opportunity for targeted and effective elimination of tumor cells. Pyruvate kinase M2 (PKM2) is predominantly expressed in proliferating cells and plays an essential role in directing glucose metabolism in cancer. Here, we report the design of novel class of selective PKM2 inhibitors as anti-cancer agents and their mechanism of action. Compound 5c being the most active with IC50  = 0.35 ± 0.07 μM, also downregulates PKM2 mRNA expression, modulates mitochondrial functionality, induces oxidative burst and is cytotoxic for various cancer types...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37216811/novel-antifungal-triazoles-with-alkynyl-methoxyl-side-chains-design-synthesis-and-biological-activity-evaluation
#18
JOURNAL ARTICLE
Fei Xie, Yumeng Hao, Liping Li, Ruina Wang, Junhe Bao, Xiaochen Chi, Brian C Monk, Ting Wang, Shichong Yu, Yongsheng Jin, Dazhi Zhang, Tingjunhong Ni, Lan Yan
Previous work led to the rational design, synthesis and testing of novel antifungal triazole analogues bearing alkynyl-methoxyl side chains. Tests of in vitro antifungal activity showed Candida albicans SC5314 and Candida glabrata 537 gave MIC values of ≤0.125 μg/mL for most of the compounds. Among these, compounds 16, 18, and 29 displayed broad-spectrum antifungal activity against seven human pathogenic fungal species, two fluconazole-resistant C. albicans isolates and two multi-drug resistant Candida auris isolates...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37210839/recent-advances-in-the-development-of-dual-alk-ros1-inhibitors-for-non-small-cell-lung-cancer-therapy
#19
REVIEW
Yingxue Li, Yanna Lv, Cheng Zhang, Binyu Fu, Yue Liu, Jinxing Hu
As a member of the insulin-receptor superfamily, ALK plays an important role in regulating the growth, proliferation, and survival of cells. ROS1 is highly homologous with ALK, and can also regulate normal physiological activities of cells. The overexpression of both is closely related to the development and metastasis of tumors. Therefore, ALK and ROS1 may serve as important therapeutic targets in non-small cell lung cancer (NSCLC). Clinically, many ALK inhibitors have shown powerful therapeutic efficacy in ALK and ROS1-positive NSCLC patients...
May 18, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37209451/discovery-of-thiohydantoin-based-antagonists-of-androgen-receptor-with-efficient-degradation-for-the-treatment-of-prostate-cancer
#20
JOURNAL ARTICLE
Xiujin Chang, Di Zhang, Fangui Qu, Youquan Xie, Tian Chen, Yuqing Zhang, Qianming Du, Jinlei Bian, Zhiyu Li, Jubo Wang, Xi Xu
Prostate cancer (PC) is one of the most prevalent cancers in men worldwide, and androgen receptor (AR) is a well-validated drug target for the treatment of PC. However, PC often exhibits resistance to AR antagonists over time. Thus, it is urgent to identify novel and effective drugs for PC treatment. A series of novel thiohydantoin based AR antagonists with efficient degradation against AR were designed, synthesized, and evaluated. Based on our previous SAR and further structural optimization, a tool molecule 26h was discovered with dual mechanisms including improved antagonistic activity and potent degradation (AR-fl and AR-V7)...
May 18, 2023: European Journal of Medicinal Chemistry
journal
journal
24926
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.